FEDERAL COURT OF AUSTRALIA
Peterson v Merck Sharpe & Dohme (Aust) Pty Ltd (No 5) [2010] FCA 605
Citation: Peterson v Merck Sharpe & Dohme (Aust) Pty Ltd (No 5) [2010] FCA 605 Parties: GRAEME ROBERT PETERSON v MERCK SHARPE & DOHME (AUSTRALIA) PTY LTD (ACN 000 173 508) and MERCK & CO, INC. File number: VID 451 of 2006 Judge: JESSUP J Date of judgment: 18 June 2010 Catchwords: PRACTICE AND PROCEDURE – Stay of execution – Whether appropriate for court to grant stay of judgment pending determination of appeal – Whether sufficient grounds established to displace applicant's entitlement to fruits of judgment – Whether execution of judgment would render appeal nugatory – Whether applicant's position could be protected by any practical expedient
PRACTICE AND PROCEDURE – Costs – Representative proceeding – Whether applicant entitled to costs generally – Whether entitlement to costs should be qualified by reference to unsuccessful causes of action – Whether costs should be taxed forthwith or await determination of appeal or conclusion of proceeding – Whether appropriate for applicant to be reserved leave to apply for costs to be taxed on indemnity basis
PRACTICE AND PROCEDURE – Costs – Notice to Admit – Whether respondents should pay for applicant's proof of facts set out in Notices to Admit
PRACTICE AND PROCEDURE – Costs – Sanderson order – Whether applicant should pay second respondent's costs when respondents jointly represented – Whether applicant's obligation to pay all or part of second respondent's costs should be transferred to first respondent – Whether first respondent's conduct in the proceeding combined with circumstances regarding corporate structure of respondents made such an order appropriate
Legislation: Federal Court Rules O 62 rr 3(3) and 24 Cases cited: Courtney v Medtel Pty Limited (No 3) [2004] FCA 347
Dr Martens Australia Pty Ltd v Figgins Holdings Pty Ltd (No 2) [2000] FCA 602
Krueger Transport Equipment Pty Ltd v Glen Cameron Storage and Distribution Pty Ltd (No 3) [2008] FCA 1592
Lackersteen v Jones (No 2) (1988) 93 FLR 442
Meadow Gem Pty Ltd v ANZ Executors and Trustees (unreported, Supreme Court of Victoria, Byrne J, 11 June 1996
Peterson v Merck Sharpe & Dohme (Australia) Pty Ltd [2010] FCA 180
Port of Melbourne Authority v Anshun Pty Ltd (1981)
147 CLR 589
Powerflex Services Pty Ltd v Data Access Corporation (1996) 67 FCR 65
Sanderson v Blyth Theatre Company [1903] 2 KB 533Date of hearing: 7 May 2010 Date of last submissions: 21 May 2010 Place: Melbourne Division: GENERAL DIVISION Category: Catchwords Number of paragraphs: 68 Counsel for the Applicant: Mr J W K Burnside QC with Mr G Dalton Solicitor for the Applicant: Slater & Gordon Counsel for the Respondents: Mr P R Garling SC with Mr G Williams Solicitor for the Respondents: Clayton Utz
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
GENERAL DIVISION
VID 451 of 2006
BETWEEN: GRAEME ROBERT PETERSON
ApplicantAND: MERCK SHARPE & DOHME (AUSTRALIA) PTY LTD
(ACN 000 173 508)
First Respondent
Keep reading for free
Create a free CaseChat account to read Peterson v Merck Sharpe & Dohme (Aust) Pty Ltd (No 5) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2010] FCA 605
- Decision Date
CaseChat Overview and Summary
The Federal Court of Australia granted Peterson judgment against Merck Australia for his claims under sections 74B and 74D of the Trade Practices Act 1974 (Cth), in the amount of $330,465.35. The execution of this judgment was stayed for 28 days. The stay could be extended pending the hearing and determination of an appeal or application for leave to appeal filed by Merck Australia within the specified period. The court dismissed Peterson's claims against Merck Australia for negligence and under sections 75AD and 82 of the Trade Practices Act 1974 (Cth). It also dismissed the claims against Merck Inc and determined specific issues as set out in the Schedule to the orders. The court ordered that Peterson was to receive costs from Merck Australia, subject to certain exclusions, and that Peterson would pay Merck Australia's costs relating to specific allegations. Peterson was also ordered to pay Merck Inc's costs, subject to exclusions. The court reserved certain costs for later determination and stayed the operation of its costs orders pending any appeal. It granted Peterson leave to apply for his costs to be taxed on an indemnity basis and set time limits for appeals and applications for leave to appeal.
Orders
Orders of the court
1. On the applicant’s personal claim against the first respondent, there be judgment for the applicant on his causes of action pursuant to ss 74B and 74D of the Trade Practices Act 1974 (Cth) in the amount of $330,465.35.
2. Execution of judgment in favour of the applicant be stayed for 28 days.
3. Subject to any order of the court, if the first respondent, within 28 days –
(a) pays into court the sum referred to in the previous order; and
(b) institutes an appeal, or files an application for leave to appeal, against the making of that order;
execution of judgment in favour of the applicant be stayed pending the hearing and determination –
(c) of that appeal; or
(d) of that application; or
(e) if that application is successful, of any appeal which arises therefrom;
as the case requires.
4. The applicant’s personal claim against the first respondent in respect of his causes of action in negligence and under ss 75AD and 82 of the Trade Practices Act 1974 (Cth) be dismissed.
5. The issues set out in the schedule to the orders made by the court on 30 March 2009 be determined as set out in the Schedule to these orders.
6. The claims against the first respondent of persons who are group members only by reason of the circumstances referred to in any one or more of items (ii), (iii), (iv) and (v) of para 2(c) of the Further Amended Statement of Claim be dismissed.
7. As against the second respondent, the Application be dismissed.
8. Subject to any costs order previously made, the first respondent pay the applicant’s costs, including reserved costs and costs incurred in the Supreme Court of Victoria, other than:
(a) costs incurred only in relation to the applicant’s allegations with respect to cardiovascular conditions other than myocardial infarction;
(b) costs incurred only in relation to the applicant’s allegations in paras 19A and 27A-27E of the Further Amended Statement of Claim, save to the extent that such costs related directly to proof of representations made to the applicant’s medical practitioner or practitioners;
(c) costs incurred only because of the claim of a particular group member, or of particular group members, other than the applicant; and
(d) costs incurred only because of the joinder of the second respondent.
9. Subject to any costs order previously made, the applicant pay the first respondent’s costs incurred only in defence to the applicant’s allegations with respect to cardiovascular conditions other than myocardial infarction.
10. The following costs of the applicant and of the first respondent be reserved:
(a) costs incurred only in relation to the applicant’s allegations in paras 19A and 27A-27E of the Further Amended Statement of Claim, save to the extent that such costs related directly to proof of representations made to the applicant’s medical practitioner or practitioners; and
(b) costs incurred only because of the claim of a particular group member, or of particular group members, other than the applicant.
11. Subject to any costs order previously made, the applicant pay the second respondent’s costs, including reserved costs, other than:
(a) costs incurred jointly with the first respondent which did not relate only to the second respondent’s defence to the applicant’s claims; and
(b) costs incurred after 24 January 2008 in defence to the applicant’s allegations that the consumption of rofecoxib or Vioxx tablets increased, or materially increased, the risk of suffering a myocardial infarction.
12. Subject to any costs order previously made, the second respondent be under no obligation pursuant to O 62 r 24 of the Federal Court Rules to pay any of the applicant’s costs incurred on or before 24 January 2008.
13. Order 62 r 3(3) of the Federal Court Rules not apply with respect to any order as to costs made this day.
14. Subject to any order of the court, the operation of the previous order be stayed for 28 days, and, if any party institutes an appeal, or applies for leave to appeal, against any order made this day, pending the hearing and determination –
(a) of that appeal; or
(b) of that application; or
(c) if that application is successful, of any appeal which arises therefrom;
as the case requires.
15. The applicant have leave, by notice of motion filed and served not later than 28 days before he takes any step for the taxation of any of the costs to which he is entitled under any order made this day, to apply for those costs to be taxed on an indemnity basis.
16. Pursuant to O 52 r 15(1) of the Federal Court Rules, each party be allowed 28 days within which to institute an appeal from any order made this day.
17. Pursuant to O 52 r 10(2A) of the Federal Court Rules, each party be allowed 28 days within which to file an application for leave to appeal from any order made this day.
18. On or before 19 July 2010, each of the applicant and the first respondent serve upon the other, and file, a memorandum setting out his or its proposals for the directions that should be made for the future conduct of the proceeding.
19. The proceeding be listed for directions at 9.30 am on 21 July 2010.
SCHEDULE
Commonality
Question 1. Are any and which of the questions set out below common to the claims of the group members?
Answer: Save to the extent indicated in the answers set out below, all the questions are common to the claims of the group members.
Materially increased risk
Question 2. Is there a physiological mechanism by which the consumption of Vioxx is capable of causing any and which of the Vioxx cardiovascular conditions?
Answer: As amended by replacing “causing” with “contributing to the onset of”: In the case of myocardial infarction, yes; otherwise, no.
Question 3. If the answer to question 2 is in the affirmative, then for each such condition, what is the physiological mechanism?
Answer: The aggregation of thrombotic material in the vasculature as the result of the blocking of the production of prostacyclin by the inhibition of COX-2 in the absence of any blocking of the production of platelet thromboxane.
Question 4. Did the consumption of Vioxx increase the risk of suffering any and which of the Vioxx cardiovascular conditions?
Answer: In the case of myocardial infarction, yes; otherwise, no.
Question 5. If the answer to question 4 is in the affirmative, was the increase in risk material?
Answer: To the extent that question 4 was answered in the affirmative, yes.
Negligence
Question 6. If the answer to question 5 is in the affirmative:
(a) when, if ever, did the First Respondent (“Merck Australia”) first know that the consumption of Vioxx materially increased the risk of suffering the condition?
(b) when, if ever, ought Merck Australia have first known that that consumption of Vioxx materially increased the risk of suffering the condition?
(c) did Merck Australia owe the group members a duty to take reasonable care to avoid acts and omissions that may expose them to a material increase in the risk of suffering the condition as a consequence of consuming Vioxx tablets?
Answer: (a) & (b): Late September 2004. However, Merck Australia was first presented with a worrisome and important signal of potential cardiovascular risk associated with the consumption of Vioxx in March 2000.
(c): Yes.
Question 7. Did Merck Australia:
(a) not owe group members the duty of care alleged; or
(b) satisfy the applicable standard of care
by virtue of compliance with the relevant legislative requirements referred to in paragraph 61 (a)-(t) of the Defence to Further Amended Statement of Claim and requirements imposed upon it in respect of Vioxx tablets by the Therapeutic Goods Administration (“TGA”) pursuant to the powers granted by the Therapeutic Goods Act 1989 (Cth)?
Answer: (a) & (b): No.
Question 8. Did Merck Australia:
(a) not owe group members the duty of care alleged; or
(b) satisfy the applicable standard of care
by reason of the learned intermediary defence pleaded in paragraph 63 of the Defence to Further Amended Statement of Claim?
Answer: (a) & (b): No.
Question 9. If the answer to question 5 is in the affirmative:
(a) did Merck Australia fail to make adequate inquiries of the Second Respondent (“Merck Inc”) regarding the adverse side effects and health risks that may be associated with the consumption of Vioxx including a material increase in the risk of suffering the condition? If so, was that failure less than reasonable in all of the circumstances?
(b) Did Merck Australia fail to undertake or cause to be undertaken any or any adequate research, investigations, clinical trials or observational studies in order to ascertain the adverse side effects and health risks that may be associated with the consumption of Vioxx including a material increase in the risk of suffering the condition? If so, was that failure less than reasonable in all of the circumstances?
(c) Did Merck Australia fail to have adequate regard to the results of any research, investigations, clinical trials or observational studies undertaken or caused to be undertaken by Merck Australia, Merck Inc or others suggesting that the consumption of Vioxx materially increased the risk of suffering the condition? If so, was that failure less than reasonable in all of the circumstances?
(d) Did Merck Australia fail to provide adequate information, advice or warning to the general public or to health care professionals to the effect that the consumption of Vioxx materially increased the risk of suffering the condition? If so, was that failure less than reasonable in all of the circumstances?
(e) Did Merck Australia develop and implement a marketing strategy or campaign by which it formulated and disseminated to health care professionals in Australia any and which of the following representations about Vioxx:
(i) Vioxx has an excellent gastrointestinal safety profile compared with other non-steroidal anti-inflammatory drugs (“NSAIDs”);
(ii) Vioxx has an excellent overall safety profile compared with other NSAIDs;
(iii) Vioxx does not increase the incidence of adverse cardiovascular events;
(iv) higher rates of myocardial infarction and other cardiovascular events among persons taking Vioxx relative to persons taking other traditional NSAIDs (in particular naproxen) did not indicate that Vioxx increased the risk of suffering adverse cardiovascular events but were attributable to the fact that the consumption of naproxen produced a lower incidence of cardiovascular events because naproxen inhibits platelet aggregation in a manner similar to aspirin while Vioxx does not;
(v) the higher rates of myocardial infarction among persons taking Vioxx relative to persons taking naproxen observed in the Vioxx Gastrointestinal Outcomes Research Trial (“Vigor”) did not indicate that Vioxx increased the risk of suffering adverse cardiovascular events;
(vi) any information to the effect that Vioxx was not as safe as other NSAIDs because the consumption of Vioxx materially increased the risk of suffering the condition was incorrect, misleading, exaggerated and/or unreliable.
If so, was that conduct less than reasonable in all of the circumstances?
Answer: (a), (b) & (c): No
(d):
(i) Merck Australia failed to provide adequate information, advice or warning to healthcare professionals generally about the signal of risk referred to in the answer to question 6. Whether that failure was less than reasonable in all of the circumstances is not a common question.
(ii) Whether Merck Australia failed to provide adequate information, advice or warning to individual healthcare professionals about the signal of risk referred to in the answer to question 6 is not a common question.
(iii) Merck Australia did not fail to provide adequate information, advice or warning to the general public about the signal of risk referred to in the answer to question 6.
(e): As to the dissemination of representations to health care professionals who treated or advised individual group members, not a common question. Otherwise, not appropriate to answer.
Question 10. Was it less than reasonable in all of the circumstances, at any time before 30 September 2004, for Merck Australia to distribute Vioxx in Australia? If so, when?
Answer: No.
Question 11. Is the fact that the Product Information for Vioxx was approved by the TGA pursuant to the Therapeutic Goods Act, if proved, a complete answer to an allegation that Merck Australia was in breach of any common law duty by unreasonably failing to adequately disclose information in the Product Information?
Answer: No.
Section 52 of the Trade Practices Act 1974 (Cth)
Question 12. If the answer to question 5 is in the affirmative, did Merck Australia:
(a) label Vioxx without providing adequate information, advice or warning to the general public or to health care professionals to the effect that the consumption of Vioxx materially increased the risk of suffering the condition?
(b) market and distribute and/or supply Vioxx for sale in Australia without providing adequate information, advice or warning to the general public or to health care professionals to the effect that the consumption of Vioxx materially increased the risk of suffering the condition?
(c) develop and implement a marketing strategy or campaign by which it formulated and disseminated to health care professionals in Australia, any and which of the following representations about Vioxx:
(i) Vioxx has an excellent gastrointestinal safety profile compared with other NSAIDs;
(ii) Vioxx has an excellent overall safety profile compared with other NSAIDs;
(iii) Vioxx does not increase the incidence of adverse cardiovascular events;
(iv) higher rates of myocardial infarction and other cardiovascular events among persons taking Vioxx relative to persons taking other traditional NSAIDs (in particular naproxen) did not indicate that Vioxx increased the risk of suffering adverse cardiovascular events but were attributable to the fact that the consumption of naproxen produced a lower incidence of cardiovascular events because naproxen inhibits platelet aggregation in a manner similar to aspirin while Vioxx does not;
(v) the higher rates of myocardial infarction among persons taking Vioxx relative to persons taking naproxen observed in Vigor did not indicate that Vioxx increased the risk of suffering adverse cardiovascular events;
(vi) information to the effect that Vioxx was not as safe as other NSAIDs because the consumption of Vioxx materially increased the risk of suffering the condition was incorrect, misleading, exaggerated and/or unreliable?
Answer: (a): Not a common question.
(b):
(i) Merck Australia marketed, distributed and supplied Vioxx for sale in Australia without providing adequate information, advice or warning to health care professionals generally about the signal of risk referred to in the answer to question 6.
(ii) Whether Merck Australia marketed, distributed and supplied Vioxx for sale in Australia without providing adequate information, advice or warning to individual healthcare professionals about the signal of risk referred to in the answer to question 6 is not a common question.
(iii) Merck Australia did not market, distribute or supply Vioxx for sale in Australia without providing adequate information, advice or warning to the general public about the signal of risk referred to in the answer to question 6.
(c): As to the dissemination of representations to health care professionals who treated or advised individual group members, not a common question. Otherwise, not appropriate to answer.
Question 13. If Merck engaged in any of the conduct referred to in question 12 was any of that conduct in trade or commerce within the meaning of the Trade Practices Act? If so, which conduct?
Answer: Merck Australia’s promotional interactions with prescribers were in trade and commerce within the meaning of the Trade Practices Act.
Question 14. Was any of the conduct identified in question 12, in all of the circumstances and context in which it occurred, misleading or deceptive or likely to mislead or deceive in contravention of section 52 of the Trade Practices Act?
Answer: As to the conduct identified in answer 12(b)(i): Until 16 November 2001, yes; otherwise, no.
Question 15. Upon the proper construction of the Therapeutic Goods Act, does the fact that the Product Information for Vioxx was approved by the TGA pursuant to the Therapeutic Goods Act, if proved, exclude the operation of the Trade Practices Act in so far as an allegation is made that a failure to adequately disclose information in the Product Information contravenes:
(a) section 52 of the Trade Practices Act?
(b) section 75AD of the Trade Practices Act?
Answer: (a) & (b): No.
Question 16. Is the fact that Vioxx was registered on the Australian Register of Therapeutic Goods pursuant to the Therapeutic Goods Act and available only by prescription of permitted prescribers, and that the Product Information for Vioxx was approved by the TGA pursuant to the Therapeutic Goods Act, if proved, a complete answer to an allegation that the respondent contravened:
(a) section 52 of the Trade Practices Act;
(b) section 75AD of the Trade Practices Act;
by failing to adequately disclose information in the Product Information?
Answer: (a) & (b): No.
Sections 75AD, 74B and 74D of the Trade Practices Act 1974 (Cth)
Question 17. Were Vioxx tablets manufactured by Merck Australia “goods” that were "ordinarily acquired" as defined in section 74A(2) of the Trade Practices Act?
Answer: Yes.
Question 18. Is the fact that Vioxx was registered on the Australian Register of Therapeutic Goods pursuant to the Therapeutic Goods Act and available in its approved form and packaging only by prescription of permitted prescribers, if proved, sufficient to establish as a matter of law that Vioxx was reasonably fit for purpose within the meaning of s74B of the Trade Practices Act?
Answer: No.
Question 19. Is the fact that Vioxx was registered on the Australian Register of Therapeutic Goods pursuant to the Therapeutic Goods Act and available in its approved form and packaging only by prescription of permitted prescribers, if proved, sufficient to establish as a matter of law that Vioxx was of merchantable quality within the meaning of s74D of the Trade Practices Act?
Answer: No.
Question 20. If the answer to question 5 is in the affirmative, were Vioxx tablets defective within the meaning of section 75AD of the Trade Practices Act in that the safety of Vioxx tablets was not such as persons are generally entitled to expect by reason of the fact that the consumption of Vioxx materially increased the risk of suffering the condition?
Answer: In the absence of any information, advice or warning, addressed to a particular group member or to his or her medical practitioner, to the effect that the consumption of Vioxx materially increased the risk of myocardial infarction, yes.
Question 21. If the answer to question 5 is in the affirmative, were Vioxx tablets defective within the meaning of section 75AD of the Trade Practices Act in that the safety of Vioxx was not such as persons are generally entitled to expect by reason of the fact that the packaging and labelling of Vioxx and the Vioxx product information did not contain adequate information, advice or warning to the effect that the consumption of Vioxx materially increased the risk of suffering the condition?
Answer: With respect to packaging and labelling, not a common question. With respect to the Product Information, the absence of any adequate information, advice or warning therefrom was a circumstance which, together with others, made the safety of Vioxx not such as persons generally were entitled to expect within the meaning of s 75AD.
Question 22. If the answer to question 5 is in the affirmative, were Vioxx tablets not reasonably fit for the purpose of acquisition within the meaning of section 74B of the Trade Practices Act by reason of the fact that the consumption of Vioxx materially increased the risk of suffering the condition?
Answer: Not a common question.
Question 23. If the answer to question 5 is in the affirmative, were Vioxx tablets not of merchantable quality within the meaning of section 74D of the Trade Practices Act by reason of the fact that the consumption of Vioxx materially increased the risk of suffering the condition?
Answer: Not a common question.
Question 24. If the answer to question 5 is in the affirmative, at all times before 30 September 2004 was the state of scientific or technical knowledge such as to enable Merck Australia to discover that the consumption of Vioxx materially increased the risk of suffering the condition?
Answer: No.
Question 25. Were the defects pleaded in paragraphs 33, 34 and 37 of the Further Amended Statement of Claim (if found to exist) caused by Merck Australia’s compliance with a mandatory standard or standards?
Answer: No.
Claim against Merck Inc
Question 26. If the answer to question 5 is in the affirmative:
(a) when did Merck Inc first know that the consumption of Vioxx materially increased the risk of suffering the condition?
(b) when ought Merck Inc to have first known that the consumption of Vioxx materially increased the risk of suffering the condition?
(c) did Merck Inc owe the group members a duty to take reasonable care to avoid acts and omissions that may expose them to a material increase in the risk of suffering the condition as a consequence of consuming Vioxx?
Answer: (a) & (b): Late September 2004. However, Merck Inc was first presented with a worrisome and important signal of potential cardiovascular risk associated with the consumption of Vioxx in March 2000.
(c): Yes.
Question 27. Did Merck Inc:
(a) not owe group members the duty of care alleged; or
(b) satisfy the applicable standard of care
by virtue of Merck Australia’s compliance with the relevant legislative requirements referred to in paragraphs 23(a)-(1) of the Defence to Amended Statement of Claim and the requirements imposed upon Merck Australia by the TGA pursuant to the powers granted by the Therapeutic Goods Act?
Answer: (a) & (b): No.
Question 28. Did Merck Inc:
(a) not owe group members the duty of care alleged; or
(b) satisfy the applicable standard of care
by reason of the learned intermediary defence pleaded in paragraph 24 of the Defence to the Further Amended Statement of Claim?
Answer: (a) & (b): No.
Question 29. If the answer to question 5 is in the affirmative:
(a) did Merck Inc fail to undertake or cause to be undertaken any or any adequate research, investigations, clinical trials or observational studies in order to ascertain the adverse side effects and health risks that may be associated with the consumption of Vioxx including a material increase in the risk of suffering the condition? If so, was that failure less than reasonable in all of the circumstances?
(b) did Merck Inc fail to have adequate regard to the results of any research, investigations, clinical trials or observational studies undertaken or caused to be undertaken by Merck Inc or others suggesting that the consumption of Vioxx materially increased the risk of suffering the condition? If so, was that failure less than reasonable in all of the circumstances?
(c) Did Merck Inc withhold from and fail to publish in medical publications or otherwise reveal data and information of which it was aware concerning adverse cardiovascular risks associated with the consumption of Vioxx? If so, was that failure less than reasonable in all of the circumstances?
(d) Did Merck Inc fail to provide to Merck Australia, and health care professionals in Australia or the Australian public any or any adequate information, advice or warning to the effect that the consumption of Vioxx materially increased the risk of suffering the condition? If so, was that failure less than reasonable in all of the circumstances?
Answer: (a), (b), (c) & (d): No.
Question 30. Was it less than reasonable in all of the circumstances at any time before 30 September 2004 for Merck Inc to supply Vioxx to Merck Australia in Australia? If so, when?
Answer: No.
Note:
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi